Skip to main content Skip to main navigation menu Skip to site footer
Reviews
Published: 2020-08-28

Personalized approach in the treatment of mental disorders: Long-term prospects for the use of low doses of psychotropic drugs.

Department of Psychosomatic Medicine and Psychotherapy, Bogomolets National Medical University
рersonalized therapy off-label psychotropic medications mental disorders low doses small doses psychotropic medications

Abstract

Importance. Despite the fact that in recent decades a large number of new psychotropic medication have been developed and investigated, psychotherapy and other treatments for mental disorders, it became apparent that many patients are resistant to treatment or response only after repeated changes in therapy or its combinations. Having a diagnosis of mental disorder itself was not sufficient to choose the best treatment. In the medical field, there is a new approach to the treatment of mental disorders - "personalized approach", which will treat not "diagnosis" but "patient".

Materials and methods. In order to observe the prospects of using low doses of psychotropic drugs (and their combinations) to achieve more effective treatment results, a content analysis was conducted using Ukrainian and English publications for the last 15 years. The search was performed on the databases Pubmed, CrossRef.

Results. The most effective drug is selected by the doctor based on the clinical condition and symptoms of the patient, but the most important factor in achieving successful results is the individually selected effective dose. Timely dose adjustment to achieve the desired clinical response, combined with the prevention of adverse reactions, is an important factor in maintaining patient's adherence to treatment.

Reducing the dose of psychotropic drugs to levels below those recommended in the instructions for use can lead to significant positive results due to: improved health care in general with more effective therapeutic results, reduced side effects and reduced patient`s costs.

Personalized approach and judicious use of psychotropic drugs for other purposes is considered an integral part of the continuous development of science, taking into account the clinical experience of the use of drugs.

Conclusions. There is a need to adjust the dosage of psychotropic drugs to the minimum effective dose that will meet the individual needs of the individual patient, and will help to find a balance between efficacy and risk of side effects and will be a necessary basis for developing an effective personalized approach in psychiatric practice.

Optimizing the dosage of a psychotropic drug is an important factor in improving the efficiency of the health care system as a whole.

Full-text of the article is available for this locale: Українська.

References

  1. Аsanova A, Khaustova O. Typical difficult situations in doctor-patient interactions. Psychosomatic medicine and general practice. 2018;3(3):1-12. doi:https://doi.org/10.26766/pmgp.v3i3.125
  2. Ozomaro U, Wahlestedt C, Nemeroff C. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11. doi:https://doi.org/10.1186/1741-7015-11-132
  3. Menke A. Precision pharmacotherapy: psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. J Pharmgenomics Pers Med. 2018;11:211-22. doi:https://doi.org/10.2147/PGPM.S146110
  4. Alda M. Personalized psychiatry: many questions, fewer answers. Psychiatry Neuroscience. 2013;38(6):363-5. doi:https://doi.org/10.1503/jpn.130221
  5. European Medicines Agency and US Food and Drug Administration Strengthen Collaboration in Pharmacovigilance Area. European Medicines Agency; 2014.
  6. On Approval of the Statute of the State Enterprise "State Pharmacological Center" Of the Ministry of Health of Ukraine Order of July 10, 2008 N 149-O. MHU; 2008.
  7. Khanra S, Das B. Off-label Psychotropics Use: Isn’t it Now an Inevitable and a “Norm” in Psychiatry? Indian J Psychol Med. 2018;40(4):390-1. doi:https://doi.org/10.4103/IJPSYM.IJPSYM_563_17
  8. Stafford R. Regulating off-label drug use—rethinking the role of the FDA. New England Journal of Medicine. 2008;358(14):1427-9. doi:https://doi.org/10.1056/nejmp0802107
  9. Depression: How Effective Are Antidepressants. IQWiG; 2015.
  10. Huskamp H. Pharmaceutical cost management and access to psychotropic drugs: The US context. Int J Law Psychiatry. 2005;28(5):484-95. doi:https://doi.org/10.1016/j.ijlp.2005.08.004
  11. Mitchell A, Selmes T. Why don’t patients attend their appointments, Maintaining engagement with psychiatric services. Advances in Psychiatric Treatment. 2007;13(6):423-34. doi:https://doi.org/10.1192/apt.bp.106.003202
  12. Daughton C, SueRuhoy I. Lower-dose prescribing: Minimizing “side effects” of pharmaceuticals on society and the environment. 2013;443(15):324-337. doi:https://doi.org/10.1016/j.scitotenv.2012.10.092
  13. Hyland M. A tale of two therapies: psychotherapy and complementary and alternative medicine (CAM) and the human effect. Clin Med. 2005;5:361-7. doi:https://doi.org/10.7861/clinmedicine.5-4-361
  14. Lake J, Turner M. Urgent Need for Improved Mental Health Care and a More Collaborative Model of Care. Perm J. 2017;21:17-024. doi:https://doi.org/10.7812/TPP/17-024
  15. Bloch S. The art of psychiatry. World Psychiatry. 2005;4(3):130-4.
  16. Woolf S, Grol R, Hutchinson A. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318(7182):527-30. doi:https://doi.org/10.1136/bmj.318.7182.527
  17. Rosoff P, Coleman D. The case for legal regulation of physician’s off label prescribing. Notre Dame Law Review. 2011;86:649-92.
  18. Gardner D. Competent Psychopharmacology. Can J Psychiatry. 2014;59(8):406-11. doi:https://doi.org/10.1177/070674371405900802
  19. O’Brien P, Cummings N, Mark TO-LP of PM, 2005–2013: AE of PI. Psychiatr Serv. 2017;68(6):549-58. doi:https://doi.org/10.1176/appi.ps.201500482
  20. Pies R. Should Psychiatrists Use Atypical Antipsychotics to Treat Nonpsychotic Anxiety? Psychiatry (Edgmont). 2009;6(6):29-37.
  21. Brophy S, Kennedy J, Fernandez-Gutierrez F. Characteristics of Children Prescribed Antipsychotics: Analysis of Routinely Collected Data. J Child Adolesc Psychopharmacol. 2018;28(3):180-91. doi:https://doi.org/10.1089/cap.2017.0003
  22. Varma S, Sareen H, Trivedi J. The Geriatric Population and Psychiatric Medication. Mens Sana Monogr. 2010;8(1):30-51. doi:https://doi.org/10.4103/0973-1229.58818
  23. Xu Y. ’Less is more’ in the Chinese context. Shanghai Arch Psychiatry. 2015;27(6):371-3. doi:https://doi.org/10.11919/j.issn.1002-0829.215106
  24. Paris J. The Use and Misuse of Psychiatric Drugs, an Evidence-Based Critique. John Willey&Sons Ltd; 2010.
  25. Mojtabai R, Olfson M. National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry. Arch Gen Psychiatry. 2010;67(1):26-36. doi:https://doi.org/10.1001/archgenpsychiatry.2009.175
  26. Pérez-Jover V, Mira J, Carratala-Munuera C, et al. Inappropriate Use of Medication by Elderly, Polymedicated, or Multipathological Patients with Chronic Diseases. J Environ Res Public Health. 2018;15(2). doi:https://doi.org/10.3390/ijerph15020310
  27. Garfinkel D, Mangin D. Feasibility Study of a Systematic Approach for Discontinuation of Multiple Medications in Older Adults: Addressing Polypharmacy. Arch Intern Med. 2010;170(18):1648-54. doi:https://doi.org/10.1001/archinternmed.2010.355
  28. Levinson D. Testimony before the United States Senate Special Committee on Aging “Overprescribed: The Human and Taxpayers’ Costs of Antipsychotics in Nursing Homes”. Dirksen Senate; 2011.
  29. Cascade E, Kalali A, Citrome L. Antipsychotic Use Varies by Patient Age. Psychiatry (Edgmont). 2007;4(7):20-3.
  30. Stroup T, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-56. doi:https://doi.org/10.1002/wps.20567
  31. Semahegn A, Torpey K, Manu A. Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis. Syst Rev. 2020;9(1). doi:https://doi.org/10.1186/s13643-020-1274-3
  32. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1). doi:https://doi.org/10.1186/s40345-016-0068-y
  33. Chaban O, Khaustova O, Omelianovych V. Emergency Care in Psychiatry and Narcology: Monograph. Publishing House Knyha; 2019.
  34. Perucca E. Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value. Epilepsy Curr. 2009;9(6):153-7. doi:https://pubmed.ncbi.nlm.nih.gov/19936129/
  35. Díaz-Caneja C, Espliego A, Parellada M, Arango C, Moreno C. Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacol. 2014;17(7):1063-82. doi:https://doi.org/10.1017/S1461145712001265
  36. Chanen A, Thompson K. Prescribing and borderline personality disorder. Aust Prescr. 2016;39(2):49-53. doi:https://doi.org/10.18773/austprescr.2016.019
  37. Green B, Korell J, Remmerie B. Optimizing Antipsychotic Patient Management Using Population Pharmacokinetic Models and Point‐of‐Care Testing. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):573-5. doi:https://doi.org/10.1002/psp4.12212
  38. Cattaneo A, Ferrari C, Uher R, et al. Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients. International Journal of Neuropsychopharmacology. 2016;19(10). doi:https://doi.org/10.1093/ijnp/pyw045
  39. Ingersolld K, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31(3):213-24. doi:https://doi.org/10.1007/s10865-007-9147-y
  40. McCormack J, , Allan G. Is bigger better, an argument for very low starting doses. CMAJ. 2011;183(1):65-9. doi:https://doi.org/10.1503/cmaj.091481
  41. Kampermann L, Nestoriuc Y, Shedden-Mora M. Physicians’ beliefs about placebo and nocebo effects in antidepressants – an online survey among German practitioners. 2017;12(5). doi:https://doi.org/10.1371/journal.pone.0178719
  42. Coupland C, Hill T, Morriss R. Antidepressant use and risk of adverse outcomes in people aged 20–64 years: cohort study using a primary care database. BMC Medicine. 2018;16(1). doi:https://doi.org/10.1186/s12916-018-1022-x
  43. Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogues Clin Neurosci. 2005;7(3):249-62.